{"analyses":[{"ciLowerLimit":"0.689","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.017","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0732","paramType":"Hazard Ratio (HR)","paramValue":"0.837","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.9","upperLimit":"19.7","value":"17.0"},{"groupId":"OG001","lowerLimit":"11.9","upperLimit":"17.7","value":"13.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"483"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"description":"OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.","id":"OG001","title":"Arm B (Nab-Paclitaxel+Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 41 months after first subject enrolled","title":"OS as Determined by the Investigator Using Recist v1.1 in the ITT Population","type":"SECONDARY","unitOfMeasure":"Months"}